Blue Jet Healthcare to invest ₹23 billion in Andhra Pradesh pharma complex targeting FY29 commissioning

Blue Jet Healthcare will invest approximately ₹23 billion to establish a greenfield pharmaceutical manufacturing complex in Andhra Pradesh’s Rambilli Industrial Park. The phased project, expected to be operational by FY2028–29, will expand capacity for contrast media intermediates and specialty chemicals while creating 2,000 jobs.

Blue Jet Healthcare will develop a new pharmaceutical manufacturing facility at Rambilli Industrial Park in Anakapalli district, Andhra Pradesh, with a planned investment of about ₹23 billion. According to official disclosures, the project will span more than 102 acres near Visakhapatnam and is scheduled for phased commissioning, with full operations targeted by FY2028–29. A ground-breaking ceremony is set for February 28, 2026.

The plant will manufacture contrast media intermediates, high-intensity sweeteners, and products from multipurpose chemistry units. The investment is expected to generate approximately 1,750 direct jobs and 250 indirect roles, reinforcing the industrial base of the Visakhapatnam economic region and supporting India’s broader specialty chemicals and pharmaceutical value chain.

Blue Jet Healthcare, an India-based pharmaceutical and specialty chemicals manufacturer, supplies niche intermediates to global markets. The new facility incorporates an advanced effluent treatment system with marine discharge connectivity and zero liquid discharge technology. The company states the design aims to lower energy consumption by roughly 70% while enabling recovery of up to 95% of wastewater.

The expansion aligns with tightening environmental, social, and governance requirements across global pharmaceutical supply chains. For manufacturers and investors, the project underscores continued capacity build-out in India’s pharma and specialty chemicals sector, particularly in coastal industrial clusters with export infrastructure advantages.